ScholarIQanswers from OpenAlex
Dallas Diabetes Research Center
InstitutionResearch output, impact & collaborations
Dallas Diabetes Research Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Dallas Diabetes Research Center?
ScholarIQrecord summary
Dallas Diabetes Research Center is a research organisation in Dallas, US. OpenAlex records 483 works and 78,275 citations for it.
How many works does Dallas Diabetes Research Center have?
ScholarIQindexed works
Dallas Diabetes Research Center has 483 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Dallas Diabetes Research Center have?
ScholarIQcitation count
Dallas Diabetes Research Center has 78,275 citations in the OpenAlex counts ScholarIQ stores.
What is the average h-index at Dallas Diabetes Research Center?
ScholarIQavg h-index
Dallas Diabetes Research Center has an average h-index of 120 in OpenAlex.
What is the ROR of Dallas Diabetes Research Center?
ScholarIQror
The ROR for Dallas Diabetes Research Center is on the source record.
What is the OpenAlex record for Dallas Diabetes Research Center?
ScholarIQopenalex
The OpenAlex for Dallas Diabetes Research Center is on the source record.
Who are the most-cited researchers behind Dallas Diabetes Research Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Dallas Diabetes Research Center?
ScholarIQmost cited works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara McGowan, Julio Rosenstock, Marie Thi Dao Tran, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F. Kushner
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, Federico C. Pérez Manghi, Laura Fernández Landó, Brandon K. Bergman, Bing Liu, Xuewei Cui, Katelyn Brown
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar, Matthew M.Y. Lee, Søren Lund Kristensen, Kelley R. Branch, Stefano Del Prato, Nardev S. Khurmi, Carolyn S.P. Lam, Renato D. Lópes, John J.V. McMurray, Richard E. Pratley, Julio Rosenstock, Hertzel C. Gerstein
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E. Schmidt, Eduard Montanya, Jason Brett, Marcin Zychma, Lawrence Blonde
How much of the research on Dallas Diabetes Research Center is open access?
ScholarIQopen access share
75%OPEN ACCESS